Starpharma Holdings

Starpharma Holdings EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Starpharma Holdings (SPL.AX) as of Nov 2, 2026 is -19.23 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -12.00 M AUD — a change of 60.29% (lower).

EBITDA

-19.23 MAUD

YoY

60.29%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Starpharma Holdings is 2026 -19.23 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Starpharma Holdings was 2025 -12.00 M AUD. It decreases by 60.29% lower compared to the previous year.

The Starpharma Holdings EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-14.25 M AUD
Jan 1, 2020
-21.43 M AUD
Jan 1, 2021
-28.67 M AUD
Jan 1, 2022
-23.90 M AUD
Jan 1, 2023
-24.67 M AUD
Jan 1, 2024
-15.16 M AUD
Jan 1, 2025
-12.00 M AUD
Jan 1, 2026
-19.23 M AUD
The Starpharma Holdings EBITDA history
YEAREBITDAYoY
-19.23 MAUD+60.29%
-12.00 MAUD-20.85%
-15.16 MAUD-38.56%
-24.67 MAUD+3.26%
-23.90 MAUD-16.65%
-28.67 MAUD+33.79%
-21.43 MAUD+50.34%
-14.25 MAUD+38.59%
-10.29 MAUD-32.41%
-15.22 MAUD-28.53%
-21.29 MAUD+12.38%
-18.95 MAUD+29.51%
-14.63 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starpharma Holdings Stock analysis

What does Starpharma Holdings do? Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starpharma Holdings stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Starpharma Holdings is -19.23 M AUD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Starpharma Holdings changed from -12.00 M AUD to -19.23 M AUD, representing a 60.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Starpharma Holdings since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Starpharma Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Starpharma Holdings

All Key Metrics — Starpharma Holdings